Schizophrenia Study
Doctors, Health-Care Professionals and Researchers
About the Study
Specific Aims
Study Synopsis
Study Locations
Site Recruitment
Ancillary Studies
Publication Policy
 
Patients and Families
About the Study
Study Locations
 

Specific Aims

The CATIE Schizophrenia Trial is a randomized controlled trial that will evaluate the effectiveness of atypical and conventional antipsychotic medications in patients with schizophrenia over a 24 month period.

  1. To determine the long-term effectiveness and tolerability (all-cause treatment discontinuation) of the newer atypical antipsychotics, relative to each other.This will involve contrasting treatment with olanzapine vs. treatment with quetiapine vs. treatment with risperidone vs. treatment with ziprasidone.
  2. To determine the long-term effectiveness and tolerability of the newer atypical antipsychotics relative to a conventional antipsychotic (perphenazine). This will involve contrasting the oral conventional antipsychotic group with the combined newer atypical antipsychotic groups.
  3. To determine, among patients who fail treatment with an initially assigned newer atypical antipsychotic due to lack of efficacy, the long-term effectiveness and tolerability of the other newer atypical antipsychotics, relative to clozapine.
  4. To determine, among patients who discontinue treatment with an initially assigned newer atypical antipsychotic due to treatment intolerance, the long-term effectiveness and tolerability of the other newer atypical antipsychotics, relative to ziprasidone.